Previous 10 | Next 10 |
BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2020, a global effor...
BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’...
Albireo reports positive data from Phase 3 trial Albireo Pharma, Inc. (ALBO) reported positive top-line data from PEDFIC 1 trial for odevixibat. The study met both its primary endpoints. The drug candidate is a highly potent, non-systemic ileal bile acid transport inhibitor. It is being ...
Albireo Pharma (NASDAQ: ALBO ) has priced its public offering of 4M common shares at $40.00/share, for expected gross proceeds of $160M. More news on: Albireo Pharma, Inc., Healthcare stocks news, , Read more ...
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its comm...
BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stoc...
Gainers: Luby's (NYSE: LUB ) +102% . More news on: Luby's, Inc., Nikola Corporation, Albireo Pharma, Inc., Stocks on the move, , Read more ...
Albireo Pharma (NASDAQ: ALBO ) +82% as odevixibat successful in late-stage study. More news on: Albireo Pharma, Inc., Nikola Corporation, Luby's, Inc., Stocks on the move, , Read more ...
Albireo Pharma (NASDAQ: ALBO ) announces positive topline results from a Phase 3 clinical trial, PEDFIC 1 , evaluating lead drug odevixibat, an ileal bile acid transporter inhibitor, in patients with a rare inherited disorder called progressive familial intrahepatic cholestasis (PFIC)...
-Highly statistically significant reductions in both pruritus and serum bile acids- -Well tolerated with very low incidence of diarrhea- -Similar efficacy in children with PFIC1 or PFIC2- -Pivotal trial results substantiate potential for odevixibat to be first drug for PFIC pa...
News, Short Squeeze, Breakout and More Instantly...
Albireo Pharma Inc. Company Name:
ALBO Stock Symbol:
NASDAQ Market:
Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...